Bellerophon Therapeutics (BLPH) saw its loss widen to $19.14 million, or $0.60 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $7.06 million, or $0.54 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $4.78 million, compared with an operating loss of $7.09 million in the previous year period.
"Overall progress in our ongoing clinical programs has been encouraging and I am pleased with data recently reported in both PAH and in pulmonary hypertension associated with idiopathic pulmonary fibrosis "PH-IPF. We look forward to the presentation of the Phase 2 PH-IPF study at the American Thoracic Society ATS International Conference on May 21st," stated Fabian Tenenbaum, chief executive officer of Bellerophon Therapeutics. "There are currently no therapies to treat pulmonary hypertension in IPF and we believe that inhaled nitric oxide delivered by means of the INOpulse delivery system is uniquely positioned to provide targeted delivery without the systemic concerns of other therapies. In addition, we expect to communicate the results of our Phase 2 trials for INOpulse therapy to treat pulmonary hypertension associated with chronic obstructive pulmonary disease PH-COPD around mid 2017."
Working capital increasesBellerophon Therapeutics has recorded an increase in the working capital over the last year. It stood at $17.18 million as at Mar. 31, 2017, up 9.02 percent or $1.42 million from $15.76 million on Mar. 31, 2016. Current ratio was at 3.84 as on Mar. 31, 2017, up from 3.15 on Mar. 31, 2016.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]